191 related articles for article (PubMed ID: 35735428)
1. Antiangiogenic Drug-Induced Proteinuria as a Prognostic Factor in Metastatic Colorectal Cancer.
Moisuc DC; Marinca MV; Gafton B; Alexa-Stratulat T; Pavel-Tanasa M; Cianga P
Curr Oncol; 2022 May; 29(6):3996-4011. PubMed ID: 35735428
[TBL] [Abstract][Full Text] [Related]
2. Relationship Between Safety and Cumulative Bevacizumab Dose in Patients With Metastatic Colorectal Cancer Who Received Long-term Bevacizumab Treatment.
Fukuda S; Niisato Y; Tsuji M; Fukuda S; Hagiwara Y; Onoda T; Suzuki H; Tange Y; Yamada T; Yamamoto Y; Moriwaki T
Anticancer Res; 2023 May; 43(5):2085-2090. PubMed ID: 37097650
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature.
Lombardi P; Rossini D; Crespi V; Germani MM; Bergamo F; Pietrantonio F; Santini D; Allegrini G; Daniel F; Pagani F; Antoniotti C; Zaniboni A; Conca V; Latiano TP; Boccaccino A; Passardi A; Tamburini E; Masi G; Di Maio M; Cremolini C
Cancer Treat Rev; 2022 Feb; 103():102326. PubMed ID: 35016085
[TBL] [Abstract][Full Text] [Related]
4. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
Degirmenci M; Karaca B; Gorumlu G; Durusoy R; Demir Piskin G; Bozkurt MT; Cirak Y; Tunali D; Karabulut B; Sanli UA; Uslu R
Med Oncol; 2010 Sep; 27(3):585-91. PubMed ID: 19526201
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab safety in Japanese patients with colorectal cancer.
Hatake K; Doi T; Uetake H; Takahashi Y; Ishihara Y; Shirao K
Jpn J Clin Oncol; 2016 Mar; 46(3):234-40. PubMed ID: 26774113
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab.
Sagawa T; Sato Y; Hirakawa M; Hamaguchi K; Fukuya A; Okamoto K; Miyamoto H; Muguruma N; Fujikawa K; Takahashi Y; Takayama T
Sci Rep; 2020 Nov; 10(1):19815. PubMed ID: 33188279
[TBL] [Abstract][Full Text] [Related]
9. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
[TBL] [Abstract][Full Text] [Related]
10. Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study.
Yu Y; Ying J; Zhang W; Li W; Sun Y; Yang L; Cui C; Zeng Y; Zhou A
Asia Pac J Clin Oncol; 2019 Jun; 15(3):128-135. PubMed ID: 30693649
[TBL] [Abstract][Full Text] [Related]
11. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
Pentheroudakis G; Mavroeidis L; Papadopoulou K; Koliou GA; Bamia C; Chatzopoulos K; Samantas E; Mauri D; Efstratiou I; Pectasides D; Makatsoris T; Bafaloukos D; Papakostas P; Papatsibas G; Bombolaki I; Chrisafi S; Kourea HP; Petraki K; Kafiri G; Fountzilas G; Kotoula V
Clin Colorectal Cancer; 2019 Dec; 18(4):e370-e384. PubMed ID: 31402291
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
[TBL] [Abstract][Full Text] [Related]
13. Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients.
Carvalho B; Lopes RG; Linhares P; Costa A; Caeiro C; Fernandes AC; Tavares N; Osório L; Vaz R
J Neurooncol; 2020 Mar; 147(1):109-116. PubMed ID: 31974803
[TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenic therapies for metastatic colorectal cancer.
Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
[TBL] [Abstract][Full Text] [Related]
15. Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.
Feliu J; Salud A; Safont MJ; García-Girón C; Aparicio J; Losa F; Bosch C; Escudero P; Casado E; Jorge M; Bohn U; Pérez-Carrión R; Carmona A; Custodio AB; Maurel J
PLoS One; 2015; 10(1):e0116527. PubMed ID: 25602286
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
Liu X; Ou K; Ma X; Gao L; Wang Q; Zhang H; Yang L
BMC Cancer; 2022 Jul; 22(1):807. PubMed ID: 35864467
[TBL] [Abstract][Full Text] [Related]
17. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis.
Cai J; Ma H; Huang F; Zhu D; Bi J; Ke Y; Zhang T
World J Surg Oncol; 2013 Nov; 11():306. PubMed ID: 24283603
[TBL] [Abstract][Full Text] [Related]
18. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
[TBL] [Abstract][Full Text] [Related]
19. Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy.
Zhou YW; Long YX; Liu X; Liu JY; Qiu M
Future Oncol; 2022 Jul; 18(22):2453-2464. PubMed ID: 35712899
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
Lin L; Xu JM; Wang Y; Ge FJ; Liu LJ; Zhao CH; Li SS; Liu JZ; Li ZQ
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):786-90. PubMed ID: 21163073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]